Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 8—August 2018
Research

Enhanced Surveillance for Coccidioidomycosis, 14 US States, 2016

Kaitlin BenedictComments to Author , Malia Ireland, Meghan P. Weinberg, Randon J. Gruninger, Jenna Weigand, Lei Chen, Katharine Perez-Lockett, Catherine Bledsoe, Lynn Denny, Katie Cibulskas, Suzanne Gibbons-Burgener, Anna Kocharian, Emilio DeBess, Tracy K. Miller, Alicia Lepp, Laura Cronquist, Kimberly Warren, Jose Antonio Serrano, Cody Loveland, George Turabelidze, Orion McCotter, and Brendan R. Jackson
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (K. Benedict, O. McCotter, B.R. Jackson); Minnesota Department of Health, St. Paul, Minnesota, USA (M. Ireland); Michigan Department of Health and Human Services, Lansing, Michigan, USA (M.P. Weinberg); Utah Department of Health, Salt Lake City, Utah, USA (R.J. Gruninger); Southwest Utah Public Health Department, Cedar City, Utah, USA (J. Weigand); Washoe County Health District, Reno, Nevada, USA (L. Chen); New Mexico Department of Health, Las Cruces, New Mexico, USA (K. Perez-Lockett, C. Bledsoe); Ohio Department of Health, Columbus, Ohio, USA (L. Denny, K. Cibulskas); Wisconsin Division of Public Health, Madison, Wisconsin, USA (S. Gibbons-Burgener, A. Kocharian); Public Health Division, Oregon Health Authority, Portland, Oregon, USA (E. DeBess); North Dakota Department of Health, Bismarck, North Dakota, USA (T.K. Miller, A. Lepp, L. Cronquist); Pennsylvania Department of Health, Wilkes-Barre, Pennsylvania, USA (K. Warren); Louisiana Department of Health, Baton Rouge, Louisiana, USA (J.A. Serrano); Wyoming Department of Health, Cheyenne, Wyoming, USA (C. Loveland); Missouri Department of Health and Senior Services, St. Louis, Missouri, USA (G. Turabelidze)

Main Article

Table 3

Positive laboratory tests for coccidioidomycosis among patients in 14 low-endemic and nonendemic US states, 2016*

Characteristic Value
Enzyme immunoassay IgM 52 (28)
Enzyme immunoassay IgM only 20 (11)
Enzyme immunoassay IgG 40 (22)
Enzyme immunoassay IgG only 13 (7)
Enzyme immunoassay IgM or IgG 69 (37)
Enzyme immunoassay IgM or IgG only 45 (24)
Immunodiffusion 53 (29)
Immunodiffusion only
 18 (10)
Complement fixation 64 (35)
  Median highest complement fixation titer, n = 55
 8 (2–1024)
Complement fixation only 23 (12)
Complement fixation titer 1:2 only 7 (4)
Histopathology 9 (5)
Histopathology only
 1 (0.5)
Culture 53 (29)
Bronchoalveolar lavage 16 (30)
Lung tissue 16 (30)
Sputum 3 (6)
Other body site 12 (23)
Unknown body site
 6 (11)
Culture only 26 (14)
Molecular evidence 14 (8)
Culture, histopathology, or molecular evidence 61 (33)

*Values are no. (%) patients except as indicated. n values are provided for categories with <186 responses.

Main Article

Page created: July 17, 2018
Page updated: July 17, 2018
Page reviewed: July 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external